[en] The chemokine G protein-coupled receptor CC chemokine receptor 5 (CCR5) is used as an entry gate by CCR5-tropic and dual- or CCR5/CXC chemokine receptor 4-tropic strains of HIV to enter the human host cells. Thus, CCR5 antagonists (i.e., maraviroc) have been proven to be clinically effective by preventing the interaction between viral glycoprotein 120 and CCR5 and thus impeding viral entry into host cells. However, the emergence of HIV strains resistant to CCR5 antagonists has been reported in vitro and in vivo, where the virus has adapted to enter the cells via antagonist-bound CCR5. An alternative strategy that should obviate this mode of viral resistance would entail the ablation of the CCR5 portal for HIV entry from the cell surface through agonist-induced receptor internalization. Although this protective effect has been demonstrated clearly with natural CCR5 ligands, the chemoattractant properties of these chemokines have precluded them from further consideration in terms of drug development. Thus, we sought to explore the possibility of developing novel small molecules and selective CCR5 agonists devoid of eliciting chemotaxis. Indeed, the CCR5 agonists described herein were found to induce profound down-modulation of CCR5 (and not CXC chemokine receptor 4) from the cell surface and its sustained sequestration in the intracellular compartment without inducing chemotaxis in vitro. The bioactivity profile of these novel CCR5 agonists is exemplified by the compound (R)-2-(4-cyanophenyl)-N-(1-(1-(N,1-diphenylmethylsulfonamido)propan-2-yl)piperidin-4-yl)acetamide (ESN-196) that potently inhibits HIV-1 infection in human peripheral blood mononuclear cells and macrophages in vitro with potencies comparable to that of maraviroc and moreover demonstrates full activity against a maraviroc-resistant HIV-1 RU570 strain.
Aquaro S, Menten P, Struyf S, Proost P, Van Damme J, De Clercq E, and Schols D (2001) The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages. J Virol 75:4402-4406. (Pubitemid 32410153)
Aramori I, Ferguson SS, Bieniasz PD, Zhang J, Cullen B, and Cullen MG (1997) Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 coreceptor. EMBO J 16:4606-4616. (Pubitemid 27326598)
Baba M, Miyake H, Wang X, Okamoto M, and Takashima K (2007) Isolation and characterization of human immunodeficiency virus type 1 resistant to the smallmolecule CCR5 antagonist TAK-652. Antimicrob Agents Chemother 51:707-715. (Pubitemid 46185293)
Balzarini J, Van Laethem K, Peumans WJ, Van Damme EJ, Bolmstedt A, Gago F, and Schols D (2006) Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol 80:8411-8421. (Pubitemid 44384854)
Berger EA, Murphy PM, and Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17:657-700. (Pubitemid 29241137)
Blanpain C, Migeotte I, Lee B, Vakili J, Doranz BJ, Govaerts C, Vassart G, Doms RW, and Parmentier M (1999) CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 94:1899-1905. (Pubitemid 29430405)
Bolli MH, Abele S, Binkert C, Bravo R, Buchmann S, Bur D, Gatfield J, Hess P, Kohl C, Mangold C, et al. (2010) 2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem 53:4198-4211.
Chan E, Heilek-Snyder G, Cammack N, Sankuratri S, and Ji C (2006) Development of a Moloney murine leukemia virus-based pseudotype anti-HIV assay suitable for accurate and rapid evaluation of HIV entry inhibitors. J Biomol Screen 11:652-663. (Pubitemid 44315962)
Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, and Lusso P (1995) Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270:1811-1815.
Burrows JN, Cumming JG, Fillery SM, Hamlin GA, Hudson JA, Jackson RJ, McLaughlin S, and Shaw JS (2005) Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas. Bioorg Med Chem Lett 15:25-28.
Detheux M, Ständker L, Vakili J, Münch J, Forssmann U, Adermann K, Pöhlmann S, Vassart G, Kirchhoff F, Parmentier M, et al. (2000) Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J Exp Med 192:1501-1508.
Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49:4721-4732. (Pubitemid 41552605)
Escola JM, Kuenzi G, Gaertner H, Foti M, and Hartley O (2010) CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network. J Biol Chem 285:41772-41780.
Gaertner H, Cerini F, Escola JM, Kuenzi G, Melotti A, Offord R, Rossitto-Borlat I, Nedellec R, Salkowitz J, Gorochov G, et al. (2008) Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc Natl Acad Sci USA 105:17706-17711.
Galvin SR and Cohen MS (2004) The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2:33-42. (Pubitemid 39490046)
Huck J, Ooms F, Tyrchan C, and Hoveyda H (2009) inventors; Euroscreen S.A., Huck J, Ooms F, Tyrchan C, and Hoveyda H, assignees. Use of piperidine derivatives as agonists of chemokine receptor activity. World patent WO2009010478. 2009 Jan 22.
Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, et al. (2008) Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 198:1345-1352.
Kellenberger E, Springael JY, Parmentier M, Hachet-Haas M, Galzi JL, and Rognan D (2007) Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. J Med Chem 50:1294-1303. (Pubitemid 46504976)
Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S, and Dioszegi M (2008) Molecular interactions of CCR5 with major classes of small-molecule anti- HIV CCR5 antagonists. Mol Pharmacol 73:789-800. (Pubitemid 351397884)
Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, Strizki JM, Riley J, Baroudy BM, Wilson IA, et al. (2004) Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 78:2790-2807. (Pubitemid 38314338)
Lederman MM, Offord RE, and Hartley O (2006) Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 6:371-382.
Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, Clapham PR, Signoret N, Marsh M, Stangassinger M, Borlat F, et al. (1998) Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 187:1215-1224. (Pubitemid 28189111)
Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, Baroudy BM, Strizki J, and Moore JP (2005) Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338:182-199. (Pubitemid 40835936)
Moore JP and Kuritzkes DR (2009) A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS 4:118-124.
Pastore C, Picchio GR, Galimi F, Fish R, Hartley O, Offord RE, and Mosier DE (2003) Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob Agents Chemother 47:509-517. (Pubitemid 36158074)
Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, and Kuhmann SE (2007) HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361:212-228. (Pubitemid 46551222)
Ribeiro RM, Bonhoeffer S, and Nowak MA (1998) The frequency of resistant mutant virus before antiviral therapy. AIDS 12:461-465. (Pubitemid 28116154)
Sabbe R, Picchio GR, Pastore C, Chaloin O, Hartley O, Offord R, and Mosier DE (2001) Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression. J Virol 75:661-671. (Pubitemid 32037270)
Saita Y, Kodama E, Orita M, Kondo M, Miyazaki T, Sudo K, Kajiwara K, Matsuoka M, and Shimizu Y (2006) Structural basis for the interaction of CCR5 with a small molecule, functionally selective CCR5 agonist. J Immunol 177:3116-3122. (Pubitemid 44277829)
Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, et al. (1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725.
Schols D, Esté JA, Cabrera C, and De Clercq E (1998) T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1α contains mutations in the envelope gp120 but does not show switch in coreceptor use. J Virol 72:4032-4037. (Pubitemid 28188707)
Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, Endres M, Palani A, Shapiro S, Clader JW, et al. (2001) SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 98:12718-12723. (Pubitemid 33020012)
Tilton JC, Wilen CB, Didigu CA, Sinha R, Harrison JE, Agrawal-Gamse C, Henning EA, Bushman FD, Martin JN, Deeks SG, et al. (2010a) A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol 84:10863-10876.
Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, Demarest JF, Ray N, Jeffrey JL, Labranche CC, and Doms RW (2010b) HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Res Hum Retroviruses 26:13-24.
Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, et al. (2002) HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 99:395-400.
Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, Subramanian M, Flexner C, Giguel F, Leopold KE, et al. (2008) In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 82:8210-8214.
Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, and Perros M (2007) Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 81:2359-2371.
Westby M and van der Ryst E (2010) CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on. Antivir Chem Chemother 20:179-192.
Zemann B, Kinzel B, Mü ller M, Reuschel R, Mechtcheriakova D, Urtz N, Bornancin F, Baumruker T, and Billich A (2006) Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 107:1454-1458. (Pubitemid 43242381)
